\n
<\/p>\n
American healthcare faces a persistent paradox: We have extraordinary medical technology, yet patients often spend years navigating a system that treats symptoms before identifying the underlying cause of disease.<\/p>\n<\/div>\n
This dynamic is especially pronounced for children with neurological conditions such as epilepsy, developmental delay, and intellectual disability. Many families endure years of hospitalizations, emergency room visits, specialist referrals, and inconclusive tests before receiving a definitive diagnosis. Clinicians often refer to this prolonged journey as the \u201cdiagnostic odyssey.\u201d It is emotionally draining for families and deeply frustrating for physicians trying to guide care.<\/p>\n
It is also extraordinarily expensive.<\/p>\n
When the root cause of a condition remains unclear, care tends to become episodic and reactive. Children cycle through emergency departments, hospital stays, and repeated testing as clinicians attempt to manage symptoms without the benefit of a clear diagnosis.<\/p>\n<\/div>\n What makes this challenge particularly striking is that healthcare already has a powerful tool to help solve it.<\/p>\n Genomic sequencing, including exome and genome sequencing, is that tool. It is like reading the entire instruction manual for a living thing by figuring out the exact order of the chemical letters that make up its DNA. It enables clinicians to analyze thousands of genes simultaneously to potentially identify genetic causes of disease. Over the past decade, these technologies have advanced dramatically. Testing is faster, more accurate, and more widely available than ever before.<\/p>\n Clinical guidelines increasingly recommend genomic sequencing as a first-tier test for many children with neurological symptoms. Yet in practice, genomic testing is still often ordered only after years of inconclusive testing and ineffective treatment.<\/p>\n<\/div>\n In other words, the technology exists\u2014but it is not consistently used early enough in the care journey to realize its full potential.<\/p>\n Recent real-world evidence illustrates what happens when genomic insights are introduced earlier.<\/p>\nTHE HIDDEN COST OF DELAYED DIAGNOSIS<\/strong><\/h2>\n